Celution

Type: Product

Name: Celution

First reported May 19 2013 - Updated May 19 2013 - 1 reports

Cytori Updates on First Quarter 2013 Business and Financial . . .

Cytori Updates on First Quarter 2013 Business and Financial Results [Professional Services Close - Up]ProQuest Information & LearningCytori Therapeutics reports its first quarter 2013 financial results and provides updates on clinical development and ... [Published Equities.com - May 19 2013]

Entities: Cytori Therapeutics Inc, Celution, Olympus Corp, PureGraft, Joint Venture

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Investment Research Weekly Roundup including: Mwana Africa, Simba Energy and African Eagle Resources

African Eagle - LON:AFE Flash note - Dutwa project winding up 16 May 2013 African Eagle has been unable to source additional funding to develop the Dutwa nickel project. The search for a strategic partner continues, but the Dutwa project company ... [Published Proactiveinvestors United Kingdom RSS feed - May 17 2013]

Entities: Simba Energy Inc, Mwana Africa, African Eagle Resources PLC, Cytori Therapeutics Inc

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Edison Investment - Cytori - Investment summary: Hearts and burns

Home » Blogs » Cytori has reacquired the rights to its Celution device from the Olympus joint venture. This gives Cytori the full benefit of Japanese sales from H2; these could grow substantially due to government funding. Celution Q1 revenue from the ... [Published BioPortfolio - May 15 2013]

Entities: Cytori Therapeutics Inc, Celution, Joint Venture, PureGraft

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Cytori Posts First Quarter 2013 Business and Financial Results

Cytori Therapeutics reports its first quarter 2013 financial results and provides updates on clinical development and commercialization activities. In a release on May 9, the Company noted earnings details:For the first quarter of 2013, Cytori achieved ... [Published Individual.com - May 14 2013]

Entities: Cytori Therapeutics Inc, Celution, Olympus Corp, PureGraft, Joint Venture

First reported May 11 2013 - Updated May 11 2013 - 1 reports

Cytori (CYTX) Q1/13 Results – BUY

Net loss was $7.7 million, or ($0.11) per shareNet loss was $7.7 million, or ($0.11) per share for Q1/13 compared to $9.3 million, or ($0.16) per share, in Q1/12.Revenues were $3.8 million, compared to $1.5 million in Q1/12. Product and government contract ... [Published Proactive Investors USA - May 11 2013]

Entities: Cytori Therapeutics Inc, Celution, PureGraft

First reported May 09 2013 - Updated May 10 2013 - 2 reports

Cytori Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript

5:00 PM ETOperatorGood afternoon, ladies and gentlemen. Welcome to the Cytori Therapeutics First Quarter Earnings Results Call. [Operator Instructions]Before we begin, we want to advise you that over the course of the call and question-and-answer session, ... [Published Seeking Alpha - May 10 2013]

Entities: Cytori Therapeutics Inc, Celution, Athena (United States)

First reported May 02 2013 - Updated May 02 2013 - 1 reports

CYTORI THERAPEUTICS INC.: Cytori to Webcast First Quarter Financial Results on May 9

Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 9, 2013 at 5:00 PM Eastern Time.The dial-in information is as follows:Dial-In Number: +1.877.402.3914Conference ... [Published 4 Traders - May 02 2013]

Entities: Cytori Therapeutics Inc, Celution, autologous, Point-of-Care

Quotes

...with the Joint Venture, which ultimately resulted in our acquisition of Olympus' interest in the Celution technology and the JV," said Calhoun. "We are grateful for the strategic, technological and financial support Olympus has provided Cytori over the years. In partnership with them, we were able to enhance the performance of the Celution technology, improve our operational capability and increase our presence in Japan. Based on our internal capabilities to miniaturize and directly manufacture the next-generation system and the importance of protecting and controlling our supply chain and related economics, we believe this action is in the best near and long-term interest of our business."

Cytori Updates on First Quarter 2013 Business and Financial . . . [Published Equities.com - May 19 2013]

"That's very Star Wars-ish, but the Phase I trials are already out there," Schatz said. "We're going to be involved in one of them, real soon."

Scripps Clinic performs stem cell heart therapy [Published U-T San Diego - May 02 2013]

...ADRC) do zabiegów wewnątrznaczyniowych u tego samego pacjenta. "Uzyskanie prawa do oznaczenia CE rozszerzy rynko"

Autoryzacja dla Intravase(R) otwiera przed Cytori rynek zabiegów naczyniowych [Published Business Wire Health News - Feb 25 2013]

More Content

sort by: Date \| Relevance
Regenerative Medicine Markets [Published Zecco - 10 hours ago]
Cytori Updates on First Quarter 2013 Business a... [Published Equities.com - May 19 2013]
Investment Research Weekly Roundup including: M... [Published Proactiveinvestors United Kingdom RSS feed - May 17 2013]
Edison Investment - Cytori - Investment summary... [Published BioPortfolio - May 15 2013]
Cytori Posts First Quarter 2013 Business and Fi... [Published Individual.com - May 14 2013]
Cytori (CYTX) Q1/13 Results – BUY [Published Proactive Investors USA - May 11 2013]
Cytori Therapeutics Management Discusses Q1 201... [Published Seeking Alpha - May 10 2013]
Cytori Reports First Quarter 2013 Business and ... [Published Yahoo! Finance - May 09 2013]
CYTORI THERAPEUTICS INC.: Cytori to Webcast Fir... [Published 4 Traders - May 02 2013]
Cytori to Webcast First Quarter Financial Resul... [Published Business Wire - May 02 2013]
Scripps Clinic performs stem cell heart therapy [Published U-T San Diego - May 02 2013]
Cytori Case Decision Upholds FDA’s Not Substant... [Published FDA Law Blog - Mar 22 2013]
Intravase® Approval Opens Vascular Market for C... [Published EON Health & Medicine - Feb 25 2013]
L’approvazione di Intravase® apre il mercato va... [Published Business Wire Health News - Feb 25 2013]
Goedkeuring van Intravase® opent de vasculaire ... [Published Business Wire Health News - Feb 25 2013]
La aprobación de Intravase® abre las puertas de... [Published Business Wire Health News - Feb 25 2013]
L'approbation d'Intravase® permet à Cytori de s... [Published Business Wire Health News - Feb 25 2013]
Zulassung von Intravase® eröffnet Cytori den Ma... [Published Business Wire Health News - Feb 25 2013]
Autoryzacja dla Intravase(R) otwiera przed Cyto... [Published Business Wire Health News - Feb 25 2013]
Intravase® Approval Opens Vascular Market for C... [Published Business Wire Health News - Feb 25 2013]
Cytoriâs cell therapy clinical studies get nod ... [Published PharmaBiz - Oct 27 2012]
Cytori Therapeutics begins US cell therapy fail... [Published PharmaBiz - Oct 15 2012]